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Abstract: Notch pathway signaling is implicated in several human cancers. Aberrant activation and
mutations of Notch signaling components are linked to tumor initiation, maintenance, and resistance to
cancer therapy. Several strategies, such as monoclonal antibodies against Notch ligands and receptors, as
well as small-molecule ฀-secretase inhibitors (GSIs), have been developed to interfere with Notch receptor
activation at proximal points in the pathway. However, the use of drug-like small molecules to target the
downstream mediators of Notch signaling, the Notch transcription activation complex, remains largely
unexplored. Here, we report the discovery of an orally active small-molecule inhibitor (termed CB-
103) of the Notch transcription activation complex. We show that CB-103 inhibits Notch signaling in
primary human T cell acute lymphoblastic leukemia and other Notch-dependent human tumor cell lines,
and concomitantly induces cell cycle arrest and apoptosis, thereby impairing proliferation, including in
GSI-resistant human tumor cell lines with chromosomal translocations and rearrangements in Notch
genes. CB-103 produces Notch loss-of-function phenotypes in flies and mice and inhibits the growth
of human breast cancer and leukemia xenografts, notably without causing the dose-limiting intestinal
toxicity associated with other Notch inhibitors. Thus, we describe a pharmacological strategy that
interferes with Notch signaling by disrupting the Notch transcription complex and shows therapeutic
potential for treating Notch-driven cancers.
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Notch pathway signaling is implicated in several human cancers. Aberrant activation and 
mutations of Notch signaling components are linked to tumor initiation, maintenance and 
resistance to cancer therapy. Several strategies, such as monoclonal antibodies (MAbs) 
against Notch ligands and receptors, as well as small molecule -secretase inhibitors (GSIs), 
have been developed to interfere with Notch receptor activation at proximal points in the 
pathway. However, the use of drug-like small molecules to target the downstream mediators 
of Notch signaling, the Notch transcription activation complex, remains largely unexplored. 
Here, we report the discovery of an orally active small molecule inhibitor (termed CB-103) of 
the Notch transcription activation complex. We show that CB-103 inhibits Notch signaling in 
primary human T-ALL and other Notch-dependent human tumor cell lines, and 
concomitantly induces cell cycle arrest and apoptosis, thereby impairing proliferation, 
including in GSI-resistant human tumor cell lines with chromosomal translocations and 
rearrangements in Notch genes. CB-103 produces Notch loss-of-function phenotypes in flies 
and mice and inhibits the growth of human breast cancer and leukemia xenografts, notably 
without causing the dose-limiting intestinal toxicity associated with other Notch inhibitors. 
Thus, we describe a pharmacological strategy that interferes with Notch signaling by 













Significance statement  
 
The Notch signaling cascade is deregulated by oncogenic lesions in human cancers and has 
therefore become an attractive therapeutic target. Inhibitory monoclonal antibodies and small 
molecule -secretase inhibitors have been developed to target the pathway at the most 
proximal point of the cascade.  Major hurdles to the therapeutic application of these Notch 
inhibitors have been prevalent dose limiting toxicities in the intestine. Here we report 
identification and preclinical validation of a small molecule (CB-103) that inhibits the 
pathway at the level of Notch transcription complex without causing intestinal toxicity. Its 
properties and mechanism of action provide CB-103 with a more favorable therapeutic index 







Transcription factors (TF) are key mediators of cellular processes and cell states. In cancer, 
TFs are commonly deregulated indirectly by aberrant upstream signaling cascades or directly 
by pathogenic mutations and or translocations. Although in principle an attractive class of 
therapeutic targets, TFs are largely considered undruggable due to the absence of surface 
pockets amenable to effective targeting with small molecules. Thus, most currently available 
targeted cancer therapeutics aim at inhibiting oncogenic signaling pathways at the most 
proximal part of the cascade, either through antibodies against ligands or surface receptors, or 
using small molecules that inhibit the enzymatic activities of receptor-associated kinases.  
The Notch signaling cascade is one example of a pathway that has emerged as a rational 
therapeutic target in several cancers. In the adult, Notch signaling in progenitor and stem 
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cells regulates tissue homeostasis, self-renewal, and differentiation in several organs and cell 
types, including the intestine, vasculature, and hematopoietic system(1).  
Notch signaling is initiated through the interaction of a receptor and ligand on 
neighboring cells. This event results in sequential proteolytic cleavages of the receptor mediated 
by metalloproteases of the ADAM family and the -secretase multiprotein complex that liberate 
the Notch intracellular domain (NICD). NICD subsequently traffics to the nucleus, binds the TF 
RBPJ, and recruits other coactivators such as mastermind proteins (MAML1-3) and p300, 
forming a transcription activation complex that initiates the expression of downstream target 
genes(2). 
 Next-generation sequencing of cancer genomes has identified numerous oncogenic gain-of-
function mutations in NOTCH1 or NOTCH2 in B and T cell leukemias and lymphomas(3–5) and 
solid cancers such as adenoid cystic carcinoma(6) and breast carcinoma(7, 8).  These mutated or 
truncated genes encode proteins that are processed to NICD constitutively and/or have increased 
stability in their active forms, increasing the expression of target genes that deregulate cell 
growth and survival. Several strategies, such as MAbs against Notch ligands(9–11) and 
receptors(12, 13), and small molecule GSIs(14, 15), have been developed to block Notch receptor 
activation at proximal points in the pathway. Whereas MAbs have the advantage of specifically 
inhibiting individual ligands or receptors, GSIs are pan-Notch inhibitors that block signaling 
through all 4 Notch receptors(16). GSIs were originally developed for treating Alzheimer disease 
because they inhibit the cleavage of amyloid precursor protein (APP). In addition, they also block 
the proteolytic cleavage step (S3 cleavage) that generates NICD, leading to their widespread 
experimental use as Notch inhibitors(1, 14). However, GSIs also block the processing of more 
than 90 other substrates, which may complicate the interpretation of results produced by 
GSIs(16). Although both MAbs and GSIs have shown beneficial effects in preclinical Notch-
driven tumor models and clinical studies (12, 17–21), none of these Notch inhibitors have been 
clinically approved, largely due to on-target dose-limiting toxicities of the intestinal 
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epithelium(22, 23). Treatment of patients with GSI is frequently associated with diarrhea, 
vomiting, and nausea, which may be severe(24, 25). To avoid this toxicity, clinical trials in 
Notch- driven cancers have relied on intermitting dosing of GSIs(14). However, the question 
remains whether intermittent dosing strategies sustain Notch inhibition long enough to achieve 
therapeutic efficacy.  
There have also been attempts to target the pathway downstream of the -secretase 
mediated activation of Notch receptors. One is based on the finding that truncated forms of 
MAML1 that bind RBPJ-NICD complex but lack the ability to recruit other co-activators 
function in a dominant negative manner(26–28). Based on this concept, Bradner and colleagues 
synthesized a stapled peptide named SAHM1 (stapled -helical peptide derived from MAML1) 
designed to mimic dominant negative forms of MAML1(29). However, developing drug-like 
stapled peptides as therapeutics remains challenging due to manufacturing, stability and 
pharmacokinetic issues. Another approach utilized screens to identify the small molecule 
Mastermind recruitment-1 (IMR-1), which is also proposed to have dominant-negative MAML-
like activity(30). Finally, a recent report describes the identification of a small molecule that 
blocks the interaction between RBPJ and SHARP, a protein that forms a corepressor complex 
with RBPJ(31). However, this approach does not inhibit NOTCH signaling, but rather leads to 
de-repression of NOTCH target genes (31). Although all of these Notch TF complex-modulating 
compounds show inhibitory activities in cellular assays, it remains to be determined whether 
these inhibitors possess drug-like properties, as none of these compounds have been tested in 
clinical trials.  
Here, we report the discovery and preclinical validation of a novel, orally active small 
molecule (termed CB-103) that interferes with the function of the Notch transcription complex. 
CB-103 induces loss-of-function phenotypes in flies and mice and has antitumor activity in 
xenograft models of Notch addicted human leukemia and carcinoma without causing gut toxicity. 
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CB-103 possesses excellent drug-like properties and is currently being evaluated in a phase-I 
clinical trial in cancer patients. 
 
Results 
Identification of CB-103 as a Notch inhibitor  
Seeking to discover small molecule inhibitors of Notch signaling, we developed a cell-based 
co-culture assay amenable to high-throughput screening of chemical compound libraries. 
This screen utilized a co-culture system consisting of ‘signal receiving’ HeLa cells 
expressing Notch1 in combination with a Notch responsive luciferase reporter, and ‘signal 
sending’ HeLa cells expressing the Notch ligand Delta-like 4 (DL4) (Figs. 1A and B).  
A screen of 67,253 compounds from commercially available libraries identified 341 
compounds with Notch inhibitory activity. Computer-aided self-organizing mapping 
programs that cluster compounds based on structural similarities allowed reduction of the 
number of hits to 98, of which 33 were validated by a secondary screen in the same co-
culture assay. These compounds were then assayed for their ability to block signaling driven 
by a dominant active form of the Notch1 receptor (N1-ICD) (Fig. 1C). Importantly, this 
approach enables identification of compounds that act downstream of the -secretase 
mediated S3 cleavage event. Employing this strategy we identified the compound 6-(4-(tert-
butyl)phenoxy)pyridin-3-amine, hereafter named CB-103 (Fig. 1D). To assess whether CB-
103 specifically inhibits Notch1 or is also active against other Notch receptors, we tested the 
ability of CB-103 to inhibit Notch2-, Notch3-and Notch4-mediated signaling using the in 
vitro co-culture assay. CB-103 inhibited Notch signaling mediated by each of the receptors 
tested in a dose dependent manner (Figs. 1E and F). As was observed for N1-ICD (Fig. 1G), 
CB-103 was also able to block the activity of the dominant-active forms of Notch2, Notch3 
and Notch4 (N2-ICD, N3-ICD and N4-ICD respectively) (Fig. 1H). Overall, CB-103 
 7 
inhibited both ligand dependent and ligand independent Notch activation in cell-based assays, 
with IC50 values ranging from 0.9-3.9 M (Figs.1 F and H); CB-103 did not inhibit Wnt or 
Hedgehog signaling using reporter assays (SI Appendix, Fig. S1A and B). 
In light of the above data, we hypothesized that CB-103 acts to prevent Notch-
mediated transcription and thus sought to substantiate this prediction. Experiments using a 
N1-ICD-GFP fusion protein indicated that CB-103 does not prevent nuclear translocation of 
N1-ICD (Fig. 1I), excluding impaired trafficking as a mechanism of action. An alternative 
possibility is that it interferes with a functional assembly of the transcription complex. 
Consistent with this, expression of increasing amounts of the co-factor MAML1 counteracted 
the inhibitory effect of CB-103 (Fig. 1J), suggesting that CB-103 impairs the recruitment 
and/or assembly of components of the Notch transcription complex.   
 
CB-103 inhibits growth of Notch addicted human T-ALL cell lines through modulation 
of the Notch transcription complex. 
To further establish CB-103 as a bona fide Notch inhibitor, we tested its ability to directly 
inhibit the growth of Notch-dependent cancer cells by initially focusing on T-cell acute 
lymphoblastic leukemia (T-ALL). More than 50% of T-ALL patients harbor activating 
NOTCH1 mutations resulting in increased Notch signaling(3). Treatment of the NOTCH1-
mutated human T-ALL cell line RPMI-8402 and the NOTCH3-driven human TALL-1 cell 
line with CB-103 or a GSI resulted in down regulation of the Notch target genes HES1, MYC 
and DTX1 (SI Appendix, Fig. S2A and B), as well as down-regulation of NOTCH1 (SI 
Appendix, Fig. S2 C).  Interestingly, protein levels of N1-ICD were unaffected by short-term 
(6 hour) treatment with CB-103 (SI Appendix, Fig. S2C), but were significantly reduced at 
later time points (24 and 48 hours) (SI Appendix, Fig. S2D and E). In contrast, protein levels 
of RBPJ were unaffected (SI Appendix, Fig. S2 E). Simultaneous treatment of RPMI-8402 
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cells with CB-103 and a proteasome inhibitor did not restore N1-ICD levels, suggesting that 
CB-103 does not impact N1-ICD protein levels by enhancing proteasomal degradation (SI 
Appendix, Fig. S2 F). As NOTCH1 exhibits positive autoregulation in T-ALL cells, these 
results are consistent with a fall in N1-ICD levels due to inhibition of NOTCH1 transcription. 
In addition, CB-103 induced profound cell growth inhibition in both RPMI-8402 and T-
ALL1 cells (SI Appendix, Fig. S2G-H). In contrast, growth of the Notch-independent HeLa 
cell line was unaffected by either CB-103 or GSI treatment (SI Appendix, Fig. S2I). Global 
gene expression analysis of CB-103-treated NOTCH1-mutated T-ALL cell lines KOPT-K1 
and HBP-ALL further confirmed down regulation of N1-ICD-driven growth-promoting 
genes, including MYC, the main oncogenic driver directly regulated by Notch in T-ALL(32, 
33) (SI Appendix, Fig. S3A and B).  
To gain insight into the molecular mechanism underlying CB-103 inhibition of 
Notch-mediated transcription, we generated RPMI-8402 T-ALL cell lines with reduced 
sensitivity to CB-103 and then investigated a possible mechanism of insensitivity – mutation 
- by exome sequencing, motivated by the hypothesis that drug insensitivity could occur 
through gene mutations affecting the drug’s target(s)(34). Exome sequencing of CB-103 
insensitive RPMI-8402 T-ALL cells identified a G193R mutation within the BTD domain of 
RBPJ. Importantly, engineered expression of a V5-tagged RBPJ
G193R
 mutant gene in parental 
RPMI-8402 cells shifted the IC50 for CB-103 from 2.6 M to >100 M, whereas expression 
of V5-tagged WT RBPJ had minimal effects, indicating that this specific single amino acid 
change is sufficient to confer insensitivity to CB-103 treatment (Figs. 2A-C).  
Next, we performed computational docking studies. CB-103 was docked on the full 
NOTCH1 transcription complex / HES1 promoter DNA system to determine a possible 
binding mode on the native structure(35). Among the calculated binding modes, one 
confirmed the BTD domain of RBPJ as possible binding site for CB-103 and identified 
 9 
several key RBPJ amino acid residues (Fig. 2A). Expression of engineered forms of RBPJ 







, but a control mutant, V5-tagged RBPJ
G194R
, in parental RPMI-8402 
cells conferred resistance to CB-103 (Figs. 2B and C and SI Appendix, Fig. S4). Thus, 
combined docking and mutational analysis support the binding of CB-103 to this pocket in 
the BTD domain. Notably, this pocket is also important for binding of the N1-ICD RAM 
domain to CSL, providing an explanation for how CB-103 impairs the formation and activity 
of the Notch1 transcription complex. 
In further support of this model, CB-103 also interfered with recovery of N1-ICD in 
immunoprecipitates prepared from RPMI-8402 cells expressing V5-WT-RBPJ, but not from 
cells expressing V5-RBP-J
G193R
 protein (Figs. 3A and B). Furthermore, CB-103 reduced the 
occupancy of RBPJ and N1-ICD on genomic Notch-response elements associated with the 
Notch target genes HES1, DTX1, and MYC in RPMI-8402 cells expressing V5-WT-RBPJ but 
not in cells expressing the V5-RBP-J
G193R
 mutant (Fig. 3C). Taken together, these results 
strongly suggest that CB-103 inhibits Notch mediated transcription by interfering with 
assembly of the Notch1 transcription complex.  
The majority of Notch/RBPJ binding sites that mediate acute changes in gene 
expression are found in enhancers(36). These genomic response elements are of two distinct 
types, one containing monomeric RBPJ sites and the second dimeric head-to-head RBPJ sites 
separated by 15-17 base pairs, an element called a sequence-pair site (SPS) that supports 
loading of dimeric Notch TF complexes. SPS-mediated Notch signaling is important for T 
cell maturation and leukemic transformation but dispensable for T cell fate specification in 
mice (37, 38).  To determine whether CB-103 preferentially inhibited elements containing 
SPSs versus head-to-tail oriented RBPJ binding sites, we performed luciferase reporter gene 
assays. Although SPSs-driven reporters elicited a much stronger signal compared to head-to-
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tail oriented RBPJ-driven promoters, both were equally sensitive to CB-103. Thus, CB-103 
inhibits both monomeric and dimeric Notch1 TF complexes, which agrees with the proposed 
mode of action of CB-103 (SI Appendix, Fig. S5).  
Next, we performed kinetic gene expression analysis using SLAM-seq on vehicle and 
CB-103 treated RPMI-8402 T-ALL cells to investigate potential differences in the CB-103 
sensitivity of promoter- and enhancer-driven Notch target genes. Pathway analysis from the 
Hallmark collection revealed E2F targets, MYC targets, and PI3K AKT MTOR signaling as 
being the most rapidly downregulated pathways. Interestingly, the Notch target genes DTX1, 
HES1, NOTCH3 and NOTCH1, which are regulated by response elements found in promoters 
or intragenic enhancers, were downregulated faster than target genes that are regulated by 
long distance enhancers, such as MYC, GIMAP1, 5, 6 and 8, suggesting that different Notch 
target genes may have varying sensitivities and or kinetics of response to CB-103 (SI 
Appendix, Fig. S6).  
In previous studies, the stapled peptide and small molecules SAHM1 and IMR-1 were 
also claimed to target the Notch transcription complex(29, 30), and we therefore compared 
their activities with CB-103 in reporter gene assays and in Notch-driven T-ALL cells. The 
activity of SAHM1 in reporter gene assays was indistinguishable from unstapled control 
peptide, and although SAHM1 was cytotoxic, unlike CB-103, it did not downregulate MYC 
expression in RPMI-8402 T-ALL cells (SI Appendix, Fig. S7). In the same assays, we failed 
to identify any effect of IMR-1 on MYC levels, or RPMI-8402 cell growth at doses up to 10 
M (SI Appendix, Fig. S7). Thus, CB-103 acts by a markedly different mechanism than 




CB-103 function in vivo recapitulates genetic Notch loss-of-function phenotypes without 
causing gut toxicity. 
Prior to investigating the in vivo activity of CB-103, we profiled the compound to determine 
its drug-like and ADME/PK (absorption, distribution, metabolism, excretion and 
pharmacokinetic) properties (SI Appendix, Fig. S8). Then we assessed CB-103’s ability to 
affect a variety of Notch-dependent cellular processes. First, we studied the effect of CB-103 
on the development of mechanosensory organs in Drosophila, which consist of four distinct 
lineages (socket, shaft, sheath and neuron) derived from a single sensory organ precursor cell 
(39). Notch signaling loss induces aberrant sensory organ lineages, including lineages 
composed of two neurons and no sheath cells, indicative of sheath-to-neuron 
transformation(39). Treatment of developing sensory organs with CB-103 resulted in 
increased numbers of neurons, similar to the effect produced by GSI (DAPT), demonstrating 
that CB-103 inhibits Notch-dependent cell fate specification in flies (SI Appendix, Fig. S9).  
We extended these findings to mammals and investigated how CB-103 affects five 
Notch-dependent phenotypes in mice: i) development of splenic marginal zone B (MZB) 
cells; ii) thymic T cell development; iii) generation of Esam
+
 dendritic cells; iv) sprouting of 
endothelial cells; and v) induction of goblet cell differentiation in the small intestine.  Each of 
these processes strictly require Notch signaling (40–46). As expected, treatment with CB-103 







MZB cells (SI Appendix, Fig. S10B), mimicking phenotypes caused by loss of Notch2(38) or 
Dll1(39). Osmotic pump-mediated delivery to maintain sustained exposure to CB-103 
resulted in a concentration-dependent reduction of MZB cells and revealed that a level of 700 
ng/ml (2.8 M) in plasma is sufficient to inhibit Notch signaling (SI Appendix, Fig. S10C and 
D). Similarly, we observed impaired thymic T cell development (SI Appendix, Fig. S11A), 






 dendritic cells (SI Appendix, Fig. S11B), and 
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increased endothelial cell sprouting in CB-103 treated wild type mice (SI Appendix, Fig. 
S12). 
In notable contrast, CB-103 treatment did not produce the expected intestinal 
phenotype.  Genetic deletion of genes encoding Notch1 and Notch2 receptors or Dll1 and 
Dll4 ligands or RBPJ, as well as sustained treatment with potent GSIs, result in goblet cell 
metaplasia and reduced proliferation of crypt progenitor cells(40, 41, 47). Goblet cell 
metaplasia-associated intestinal toxicity is one of the main dose-limiting ‘adverse events’ in 
clinical trials using Notch targeting agents such as GSI or antagonistic Notch receptor 
antibodies(1). We treated mice with vehicle control, CB-103 or the GSI LY3039478. Mice 
treated with vehicle control or CB-103 were analyzed after one week and 4 weeks of 
treatment, while mice treated with LY3039478 were analyzed after one week due to 
treatment-related morbidity. Alcian blue and Ki67 staining revealed a dramatic increase in 
goblet cell numbers and a highly significant reduction in crypt cell proliferation in 
LY3039478 treated animals. In contrast, CB-103 treated animals showed only a moderate 
increase in goblet cell numbers and a moderate reduction in Ki67-positive crypt cells (Figs. 
4A and B).  
To investigate the basis of the milder gut phenotype in CB-103-treated mice, we 
studied its effects on key downstream target genes. In the small intestine, Notch signaling 
directly regulates the expression of the stem cell marker gene Olmf4 and members of the Hes 
family of TFs, which repress the transcriptional master regulator for secretory cells, 
Atoh1(48–50). In situ hybridization studies revealed that the expression of Olmf4 and Hes1 
was nearly completely abrogated by CB-103 and LY3039478, thereby demonstrating Notch 
inhibitory activity of these agents in the gut. By contrast, LY3039478 treated animals had 
significantly higher levels of Atoh1 transcripts compared to vehicle and CB-103 treated 
animals, which showed only a small increase in Atoh1 transcripts relative to vehicle treated 
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animals (Fig. 4B). To exclude possible confounding influences of variation in absorption or 
pharmacokinetic properties in vivo, we tested these compounds in intestinal organoid cultures 
created from wild type mice. LY3039478-treated organoids had a very different morphology 
than CB-103 treated cultures and showed increased goblet cell differentiation and decreased 
proliferation compared to vehicle or CB-103 treated organoids (SI Appendix, Fig. S13A). We 
again observed strong inhibition of the Notch pathway, as indicated by downregulation of 
direct Notch target genes Olmf4, Hes1, Hes3 and Hes5 to a similar degree by both CB-103 
and LY3039478, whereas Atoh1 transcripts were upregulated to higher levels in LY3039478 
treated organoids (SI Appendix, Fig. S13B). These results show that while both compounds 
block Notch signaling in the intestine in vivo and in intestinal organoids, goblet cell 
metaplasia and profound growth inhibition were only observed with LY3039478 treatment, 
presumably due to the higher expression levels of Atoh1.  
 
CB-103 blocks tumor growth of GSI-resistant cancers. 
A potential advantage of a small molecule inhibitor of the Notch TF complex is the ability to 
block Notch signaling in tumors that are resistant to Notch-directed MAbs or GSIs by virtue 
of Notch gene rearrangements that lead to -secretase independent Notch activation. As a 
proof of principle, we studied via lentiviral expression of constitutively nuclear N1-ICD 
whether CB-103 could inhibit growth of Notch-dependent human DND-41 T-ALL cells 
rendered resistant to agents (such as GSI) that act upstream of the Notch TF complex. As 
expected, parental DND-41 cells exhibited reduced growth inhibition and Notch signaling 
following treatment with either LY3039478 or CB-103, whereas only CB-103 elicited growth 
arrest in DND-41 cells expressing N1-ICD (SI Appendix, Fig. S14A). CB-103 sensitivity was 
in turn rescued by ectopic expression of MYC (SI Appendix, Fig. S14B), consistent with prior 
work implicating MYC as a key Notch target gene in T-ALL cells (51).  
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Next, we investigated the ability of CB-103 to inhibit growth of Notch-dependent 
cancers that are resistant to MAbs and/or GSI therapy. We focused on triple negative breast 
cancer (TNBC), since approximately 10% have rearrangements in NOTCH1 and/or NOTCH2 
that lead to constitutive, ligand-independent Notch activation(7, 8). As predicted, growth of 
the GSI-resistant HCC1187 cell line carrying a NOTCH2 rearrangement(7) was inhibited by 
CB-103 treatment but not by RO4929097, a GSI previously assessed in clinical phase I/II 
studies (8) (Fig. 5A). We subsequently established a stable luciferase reporter line to 
determine the ability of CB-103 to inhibit growth of HCC1187 following 
xenotransplantation. CB-103 treated animals showed remarkable growth inhibition and 
reduced tumor burden compared to vehicle treated animals (Fig. 5B). CCDN1, a known 
Notch target in breast cancer(52, 53), was downregulated in tumors from CB-103 treated 
animals compared to controls (Fig. 5C). Moreover, CB-103 mediated tumor growth 
inhibition was accompanied by reduced Ki67 and increased Caspase 3 staining, while CD31 
staining was similar in vehicle and CB-103 treated animals (and SI Appendix, Fig. S15). Our 
data provide proof-of-concept that CB-103 can inhibit growth of “Notch-addicted” cancer 
cells expressing mutated forms of Notch that cannot be targeted with agents that act upstream 
of the Notch TF complex. Furthermore, patient-derived xenotransplanation (PDX) 
experiments using a NOTCH1-positive oxaliplatin-resistant colorectal cancer sample(54) 
revealed that CB-103 resensitizes this tumor to oxaliplatin treatment in vivo (Fig. 5D). 
To extend these findings to primary human cancers, we investigated the ability of CB-
103 to inhibit the growth of 19 primary T-ALLs, the human tumor with the highest frequency 
of Notch gain-of-function mutations, in a co-culture model(47). Dose response profiles 
indicated that CB-103 induced growth inhibition in ~50% of the cases tested with IC50 values 
in the sub-micromolar range (Fig. 5E). Importantly, the ability of CB-103 to reduce tumor 
growth correlated strictly with Notch activation status, as only tumors containing N1-ICD 
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responded to CB-103 treatment. Furthermore, growth inhibition induced by CB-103 was 
associated with the presence of elevated levels of N1-ICD pre-treatment and decreased N1-
ICD levels post-treatment, but did not strictly correlate with the mutation status of NOTCH1, 
or FBXW7 (Fig. 5F). These results indicate that CB-103 selectively inhibits the growth of T-
ALLs with ongoing NOTCH1 activation and supports prior studies suggesting that the level 
of N1-ICD predicts tumor response to Notch pathway inhibitors(44). In line with these ex-
vivo results, CB-103 prolonged the survival of mice bearing a NOTCH1-mutated T-ALL 
PDX model compared to vehicle treatment (Fig. 5G, left panel), an antitumor effect that was 
also associated with decreased N1-ICD levels (Fig. 5G, right panels). A second independent 
N1-ICD positive T-ALL PDX model also showed significantly reduced tumor burden in mice 
with either high or low tumor burden (>20% and <2% leukemic blasts in the peripheral 





ALL blasts after CB103 treatment (Fig. 5H).   
 
Discussion 
In the last decade unbiased next generation sequencing efforts of human cancer specimens 
have identified activating genetic aberrations in NOTCH genes in a broad spectrum of 
cancers, including T-ALL, adenoid cystic carcinoma, chronic lymphocytic leukemia, 
marginal zone B cell lymphoma and breast cancer(3, 6, 7, 55). Moreover, many preclinical 
studies have implicated Notch signaling in almost all hallmarks of cancer, highlighting why 
this signaling pathway is an intriguing, but complex, therapeutic target(56). 
Herein we describe a cell-based high throughput screen that led to the identification 
and characterization of novel small molecule inhibitor (CB-103) of the Notch cascade. CB-
103 is a pan Notch inhibitor as it can block Notch-mediated signaling of all four Notch 
receptors (Fig.1), similar to GSIs. Commonly used GSIs block Notch signaling by inhibiting 
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the proteolytic activity of the -secretase multi-protein complex, which cleave Notch 
receptors at the S3 site within the transmembrane domain. In contrast to GSIs, CB-103 
evidently inhibits the pathway at the most downstream level – the Notch transcriptional 
complex – based on its ability to block GSI-insensitive dominant active forms of NICD.  
Further evidence comes from the generation of a T-ALL cell line that is resistant to CB-103. 
The rationale of this experimental design was that drug insensitivity can be afforded through 
mutations, that circumvent the inhibitory activity by the drug, mutations that have the 
potential to reveal mechanistic insights both into the actions of the drug and its target(34). In 
the past this approach has been used successfully to identify drug targets for BI 2536, a Polo-
like kinase1 inhibitor(50), as well as for the proteasome inhibitor Bortezomib, which is 
clinically used to treat multiple myeloma and mantle cell lymphoma(34, 57). Using 
transcriptome sequencing analysis, we identified a G193R mutation within the RBPJ gene, 
which encodes an essential component of the Notch transcription complex; this mutation 
confers resistance to CB-103 when introduced into Notch-driven T-ALL cells (Fig. 2). 
Notably, this mutant abrogated the ability of CB-103 to inhibit the formation of Notch 
transcription complexes, as assessed by immunoprecipitation and ChIP on endogenous 
Notch-response sites near target genes such as HES1, DTX1, and MYC (Fig. 3). In addition, 
computational docking studies identified the BTD domain of RBPJ as potential binding 
pocket for CB-103, and accurately predicted amino acids residues in RBPJ that when mutated 
confer resistance to CB-103. Taken together, the computational docking studies, mutational 
analysis as well as pulldown and ChIP experiments are in agreement with CB-103 acting as a 
direct inhibitor within the Notch transcription complex. 
 Oncogenic Notch signaling can be triggered by a variety of mutations, including 
single nucleotide substitutions, small insertion/deletion mutations, and rearrangements of 
Notch genes. One advantage of CB-103 over currently available Notch inhibitors is that it is 
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active against tumor cells bearing any of these types of mutations, which is not uniformly 
true of other Notch inhibitors. Mutated Notch receptors found in tumors with Notch gene 
rearrangements lack ectodomains and therefore do not rely on ligand for activation and 
cannot be targeted with blocking antibodies. Furthermore, approximately 5% of TNBCs and 
52% of glomus tumors have gene rearrangements in NOTCH2(7, 8, 58) in which N2-ICD 
nuclear access is not gamma-secretase dependent, as translational initiation in the aberrant 
NOTCH2 transcripts lies C-terminal of the S3 cleavage site(7). We performed proof-of-
concept experiments (Fig. 5 and SI Appendix, Fig. S14) using either engineered human T-
ALL cell lines expressing N1-ICD and the TNBC cell line HCC1187, which has a NOTCH2 
gene rearrangement. Notably, CB-103 inhibited growth of both cell lines in vitro as well as 
the growth of HCC1187 xenotransplants, whereas GSIs were inactive.  
Previous studies also identified compounds - SAHM1, IMR-1 and RIN1 - that were 
claimed to target the Notch transcription complex(29–31). However, in reassessing the 
activity of SAHM1, we were unable to confirm any “on-Notch” inhibitory effects in reporter 
gene assays or T-ALL cells (SI Appendix, Fig. S7). IMR-1 is a small chemical compound that 
was identified based on the strategy of inhibiting MAML1 recruitment to the Notch 
transcription complex(30). A side by side comparison of CB-103, the GSI LY3039478, 
SAHM1 and IMR-1 for their ability to block growth of a Notch-driven human T-ALL cell 
line showed that IMR-1 had no effect on Notch target gene expression or cell growth at doses 
up to 10 M, whereas CB-103 and GSI were active (SI Appendix, Fig. S7). IMR-1 evidently 
can inhibit Notch signaling at higher concentrations, as previously reported(30, 59, 60). RIN1 
is another small molecule that was recently reported to modulate the Notch transcription 
complex(31). This small chemical compound was identified in a reporter-based cell culture 
assay aimed at identifying inhibitors of interactions between RBPJ and SHARP, which is a 
component of a transcriptional repressor complex that binds RBPJ in the absence of NICD.  
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In line with this possibility, RIN1-treated cells upregulated Notch target genes, mimicking 
the effects of RBPJ knockdown. The activity of RIN1 has yet to be assessed, in regard to 
therapeutic efficacy and intestinal toxicity(31), and comparative evaluation with CB-103 
warrant future consideration.  
One of the major dose limiting toxicities and hurdles to the therapeutic application of 
pan-Notch inhibitor has been intestinal toxicity(22, 23). Genetic studies in mice show that 
Notch acts as a stem and progenitor cell gate keeper and is important for secretory versus 
absorptive cell fate differentiation. Conditional, gut-specific inactivation of Notch1 and 2, the 
ligands Dll1 and Dll4, and RBPJ each results in the loss of proliferative crypt progenitors and 
conversion into post-mitotic goblet cells(40, 41, 47). A similar phenotype has been observed 
in mice with simultaneous gut-specific inactivation of the Notch target genes Hes1, Hes3 and 
Hes5, indicating Notch signaling regulates intestinal homeostasis at least in part though Hes 
genes(49). Conversely, transgenic Notch gain-of-function experiments cause a reciprocal 
phenotype consisting of a block in secretory cell differentiation and an expansion of 
immature crypt progenitors(61). The gut phenotype created by knockout of Notch pathway 
components is also observed in rodents treated with potent GSIs such as dibenzazepine(47), 
suggesting that the gut toxicity caused by GSI is mostly driven by Notch inhibition(16). In 
this context it is interesting to note, that four different -secretase complexes exist and that 
most available GSI block all complexes, which is likely to account for the intestinal toxicities 
in GSI-treated animals or patients. A recent report showed that selective pharmacological 
inhibition of one (presenilin-1) of the four (PSEN) -secretase subclasses, is effective in 
reducing the leukemic burden of PSEN-1 expressing T-ALL cells in xenotransplantation 
assays without causing intestinal toxicity(62).  Thus, selective inhibition of -secretase 
complex might be a potential therapeutic strategy for safely targeting Notch-driven tumors, 
provided Notch cleavage is mostly mediated by specific PSEN subclasses.   
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These effects of GSI involve alterations in the TF Atoh1 (also known as Math1), 
which is a master regulator of the secretory lineage(50, 63). Conditional gut-specific 
inactivation of Atoh1 results in loss of all secretory cells and in the context of GSI-mediated 
Notch inhibition has been shown to be essential for goblet cell fate conversion(63).  
Unexpectedly, in vivo administration of CB-103 to mice did not lead to the 
anticipated goblet cell metaplasia phenotype, which was observed in GSI-treated animals. 
Direct Notch target genes such as Olmf4 and Hes1 were both downregulated by CB-103 and 
GSI, indicating that CB-103 reached the target tissue. By contrast, Atoh1 transcripts were 
significantly higher in GSI treated animals (Fig. 4). This distinction was confirmed in 
intestinal organoid cultures, excluding the possibility this result is a consequence of variation 
in absorption or pharmacokinetic properties in vivo. LY3039478-treated organoids displayed 
a very different morphology than CB-103-treated cultures, showing increased goblet cell 
differentiation and decreased proliferation compared to vehicle- or CB-103-treated organoids 
(SI Appendix, Fig. S13). The mechanisms underlying this distinction are currently unknown. 
Several possibilities can be considered. First, CB-103 is likely to inhibit protein-protein 
interaction and might therefore produce more incomplete Notch inhibition than a potent GSI. 
A second possibility, which is not mutually exclusive, is that CB-103 may inhibit only a 
subset of RBPJ complexes, leading to variation in the responsiveness of different Notch 
target genes. Nevertheless, in Notch-driven tumors, where the levels of signaling are well 
above that of normal tissues due to activating mutations, CB-103 is evidently potent enough 
to produce responses in preclinical models.  Further work is necessary to parse out these 
distinctions. 
In summary, our discovery and characterization of CB-103 makes a compelling case 
that small molecule inhibitors can be developed and used to block TF complexes, which are 
downstream of many aberrant signaling cascades, but have been historically intransigent to 
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therapeutic targeting. CB-103 interferes with the Notch TF complex, and may thereby convey 
a more favorable therapeutic window than previous Notch-targeting agents. Motivated by this 
knowledge and by its pharmacological characteristics, CB-103 is currently being evaluated in 
phase I/II clinical trials (https://clinicaltrials.gov/ct2/show/NCT03422679).  
 
 
Materials and Methods 
Details are provided in SI Appendix including sources of constructs, compounds, cell lines 
and cell culture conditions (ex vivo, in vitro), luciferase reporter assay, assays of cell cycle, 
proliferation, cell viability, stable transformants, and animal studies. Details of microscopy, 
image processing and analysis, FACS and computational docking studies are described in SI 
Appendix. Methods for Western blot, IP and ChIP, qRT-PCR, in situ hybridization, histology 
and immunostaining, RNA-seq and SLAM-seq, bioinformatic and statistical analyses are also 
provided in SI Appendix. 
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Fig. 1. Identification of CB-103 as a novel inhibitor of the Notch transcription activation 
complex. (A) Schematic of the Delta-like 4 (DL4) Notch1 (N1) co-culture assay used high-
throughput screening in HeLa cells. Ligand-receptor mediated pathway activation was 
measured using a Notch responsive luciferase reporter. (B) Assay validation of the DL4-N1 
co-culture screening with indicated Z’ value. Bar graph shows result of one representative 
384-well plate, half treated with 10 M of the GSI DAPT and half with vehicle control. (C) 
Schematic representation of the N1-ICD-driven luciferase reporter assay used to counter 
screen validated hits of the primary screen. (D) Chemical structure of 6-(4-(tert-
butyl)phenoxy)pyridine-3-amine (CB-103). (E) Bar graphs show concentration dependent 
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assessment of CB-103 and GSI (DAPT) to DL4-Notch1-mediated signaling in the RBPJ-
driven reporter and co-culture assay. Luciferase activity was measured 24 hours after 
treatment. (F) Dose-response curves for mNotch1, mNotch2, mNotch3 and mNotch4 
activation following treatment of co-cultures with CB-103. (G) Bar graph shows 
concentration dependent assessment of CB-103 and GSI (DAPT) to inhibit N1-ICD-
mediated, RBPJ-driven reporter assay. (H) Dose-response curves for N1-ICD, N2-ICD, N3-
ICD N4-ICD mediated RBPJ luciferase reporter assay 24 hours post CB-103 treatment. (I) 
Nuclear localization of N1-ICD-GFP fusion protein in HeLa cells in the presence of DMSO 
or CB-103 (representative of 3 independent experiments). (J) N1-ICD-induced luciferase 
activity in the presence of CB-103 and increasing amounts of MAML1. 
 
 
Fig. 2. Single amino acid mutations within the BTD domain of RBPJ cause unresponsiveness 
to CB-103 in RPMI-8402 cells. (A) Experimental structure of the NOTCH1 transcription 
complex on the HES1 promoter DNA sequence (PDB ID 3V79) (64). CSL (orange), domains 
are show in ribbon representation. HES1 backbone is shown in ribbon representation, with 
nucleotides displayed as tubes. Green arrows indicate predicted amino acids important for 
binding of CB-103 within the BTD domain of RBPJ.   (B) Graph shows dose response curves 
of CB-103 treated parental, RPBJ
wt–V5 and RBPJG193R–V5, RBPJL245A–V5, RBPJL248A–V5, 
RBPJ
F196A–V5 and RBPJG194R–V5 expressing RPMI-8402 cells. Cells were treated with CB-
103 for 3 days. IC-50 values for respective cell lines are indicated. (C) Bar graphs show 
percentage of apoptotic cells of parental, RBPJ
wt–V5 and RBPJG193R–V5, RBPJL245A–V5, 
RBPJ
L248A–V5, RBPJF196A–V5 and RBPJG194R–V5 expressing RPMI-8402 cells treated with 
DMSO or CB-103 (10 M) for 72 hours. Statistical analysis was performed using two-tailed 




Fig. 3. CB-103 inhibits assembly of the RBPJ-NICD transcription complex. (A and B) 






-V5 mutant protein (B), were 
treated with vehicle control (-) or CB-103 (+), 10 M for 14 hours and subjected to 
immunoprecipitation using a V5-specific antibody. N1-ICD immunoprecipitates were 







-V5 mutant protein expressing RPMI-8402 cells. (C) 





protein were subjected to ChIP. RBPJ binding regions from NOTCH target genes HES1, 
DTX1 and MYC were PCR amplified from input and precipitated DNA. Location of the PCR 
amplicons is schematically illustrated to the left (red dash). Results are expressed as 
percentage relative to input. Shown are mean  SD (n  3). Statistical analysis was performed 
using one-way ANOVA (**** p < 0.0001, *** p <0.0006, ** p <0.009). 
 
Fig. 4.  CB-103 reduces Notch target gene expression in the small intestine without causing 
goblet cell metaplasia. (A) Alcian blue (top panels), Ki67 staining (lower panels) and in situ 
hybridizations for expression of Notch target genes Olmf4, Hes1 and Atoh1 of representative 
sections from the proximal small intestine of vehicle, CB-103 (20 mg/kg/ 2 x day) and GSI 
(LY3039478, 20 mg/kg/ 2 x day) treated mice are shown. Mice were treated with CB-103 up 
to 4 weeks and analyzed at either 1- or 4-weeks post administration. Analysis at two time 
points revealed comparable results. CB-103 treatment at 4 weeks and GSI treatment at 1 
week is depicted. (B) Bar graphs show quantification of indicated stainings and in situ 
hybridizations. The number of Alcian blue positive cells per crypt-villus unit and Ki67 
positive cells per crypt is expressed as percentage of positive cells per field, of vehicle (n=2 
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mice, 130 crypt-villus units for Alcian blue and 462 crypts for Ki67), CB-103 (n=6 mice, 375 
crypt-villus units and 430 crypts for Ki67) and GSI (n=3 mice, 135 crypt villus-units and 330 
crypts for Ki67) treated animals. In situ hybridization of Olmf4, Hes1 and Atoh1 expression 
was quantified and is expressed as percentage of positive crypts for Olmf4 (score 4, n=2 mice 
for vehicle treated animals, 190 crypts, n=6 mice for CB-103 treatment, 600 crypts, n=3 mice 
for GSI-treated animals, 300 crypts, ), percentage of positive cells per crypt for Hes1(score 4, 
n=2 mice for vehicle treated animals, 140 crypts, n=6 mice for CB-103 treatment, 170 crypts, 
n=3 mice for GSI-treated animals, 110 crypts) and percentage of positive cells per field for 
Atoh1 expression (n=2 mice, vehicle group, 150 crypt-villus units, n=6 mice, CB-103 group, 
340 crypt-villus units, n=3 mice, LY3039478 group, 220 crypt-villus units). Scale bar for 
Alcian blue = 50m, for other slides = 20m. Statistical analysis was performed using 
unpaired t-test. (**** p < 0.0001).  
 
Fig. 5 CB-103 impedes growth of NOTCH-positive cancer cell lines and primary human T-
ALL. (A). Growth kinetics of HCC-1187 cells treated with DMSO, GSI (RO4929097) and 
CB-103 (10M each) for 6 days. (B) Luciferase-expressing HCC-1187 cells were 
subcutaneously transplanted into NOD/SCIDc-/- (NSG) mice and treated with either vehicle 
(n=6) or CB-103 (n=6) for 15d (2x/day). Bioluminescence was measured 30 days post 
transplantation. HCC-1187 tumor volume (mm
3
) measured over time in xenotransplanted 
mice treated with either vehicle or CB-103 (25mg/kg) administrated twice a day (n=6 for 
each group) is shown. Two independent experiments were performed. Statistical analysis was 
performed using two-way ANOVA **** p < 0.00001. (C)  Representative hematoxylin and 
eosin (H&E) staining (left panel) and immunostaining for Cyclin D1 (right panel) of tumors 
harvested from vehicle and CB-103 treated animals is shown. (D) Oxaliplatin-resistant M43 
colorectal cancer cells were transplanted into NSG mice and subsequently treated with either 
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vehicle (n=18), CB-103 (n=18), oxaliplatin, or oxaliplatin and CB-103 for 12 days (25 mg/kg 
1x/day) and tumor growth fold-change was monitored over time (left panel) and at end stage 
of the experiment (right panel). One-way ANOVA, Tukey’s multiple comparisons test * p < 
0.05; *** p < 0.0003; **** p < 0.0001. (E) Response to CB-103 of T-ALL cells in vitro. 
Patient derived xenografts (n=20) were maintained on human mesenchymal stromal cells and 
incubated with 0.01, 0.1, 1, 10 or 25 M CB-103 for 7 days. Graph represents IC50 values of 
each patient sample treated with CB-103. Blue circles = patient samples positive for the 
presence N1-ICD, red circles = patient samples negative for N1-ICD. (F) Immunoblots 
underneath show N1-ICD levels decrease upon treatment with CB-103. N1-ICD detection in 
indicated patient samples (numbered) on Western blot after 72 hours exposure to DMSO or 
CB-103 is shown. Mutation status for NOTCH1 and FBXW7 are indicated. (G) Event-free 
survival analysis after treatment of leukemia xenografts of the T-ALL corresponding to case 
1. Kaplan-Meier survival curve is shown for xenografted NSG mice. Treatment with vehicle 
or CB-103 as indicated when 10% of T-ALL cells were detected in peripheral blood by flow 
cytometry. Log-rank (Mantel-Cox) test and p-value as indicated. Bar graph represents 
detection levels of N1-ICD in T-ALL cells after in vivo treatment with CB-103. The mean 
ratio (+/- SEM) of N1-ICD (Val 1744) determined in vehicle and CB-103 treated animals 
(two per condition). A representative Western blot example for N1-ICD of treated animals is 
shown. (H) Bar graphs show results of a second independent N1-ICD positive PDX model 
xenografted into NSG mice. Vehicle control and CB-103 treatment groups were subdivided 
into high and low tumor burden groups based on >20% and <2% of T-ALL cells detected in 
peripheral blood by flow cytometric analysis at treatment initiation. Animal groups were 





 T-ALL cells after treatment. Animals with high tumor burden: n=5 for 
 30 
vehicle control and n=3 for CB-103 treated animals; animals with low tumor burden: n=5 for 
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